Marshall Wace’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.8M Buy
829,659
+814,659
+5,431% +$21.7M 0.02% 666
2026
Q1
$402K Sell
15,000
-343,440
-96% -$10.3M ﹤0.01% 2544
2025
Q4
$11M Sell
358,440
-174,769
-33% -$5.45M 0.01% 836
2025
Q3
$16.4M Sell
533,209
-1,374,075
-72% -$33.5M 0.02% 741
2025
Q2
$39.4M Sell
1,907,284
-274,226
-13% -$5.63M 0.04% 361
2025
Q1
$42.7M Buy
2,181,510
+1,059,214
+94% +$22.2M 0.05% 318
2024
Q4
$23.4M Buy
1,122,296
+694,243
+162% +$15.3M 0.03% 489
2024
Q3
$10.4M Sell
428,053
-220,326
-34% -$5.89M 0.01% 747
2024
Q2
$16.3M Sell
648,379
-301,046
-32% -$8.54M 0.02% 564
2024
Q1
$28.4M Buy
949,425
+734,017
+341% +$21.6M 0.04% 395
2023
Q4
$6.86M Buy
215,408
+4,609
+2% +$145K 0.01% 796
2023
Q3
$7.43M Buy
+210,799
New +$8.03M 0.02% 741
2023
Q1
Sell
-8,259
Closed -$350K 2828
2022
Q4
$350K Buy
+8,259
New +$340K ﹤0.01% 2510
2021
Q2
Sell
-8,595
Closed -$282K 2794
2021
Q1
$282K Sell
8,595
-57,447
-87% -$2.16M ﹤0.01% 2146
2020
Q4
$2.69M Sell
66,042
-158,987
-71% -$5.94M 0.01% 823
2020
Q3
$8.24M Sell
225,029
-291,274
-56% -$10.5M 0.05% 353
2020
Q2
$17.5M Buy
516,303
+279,003
+118% +$7.6M 0.12% 177
2020
Q1
$5.03M Buy
+237,300
New +$5.29M 0.05% 381

Other funds holding GMAB

Marshall Wace's GMAB Position: Q2 2026 in Review

Marshall Wace increased its Genmab (GMAB) stake by 5,431% in Q2 2026, buying an estimated $21.7M and bringing the position to 829,659 shares worth $22.8M. The position accounts for 0.02% of the portfolio, ranked #666.

Marshall Wace first reported a position in GMAB in Q1 2020 and has held it in 18 quarters since. The position peaked at $42.7M in Q1 2025. 292 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Marshall Wace held 829,659 shares of Genmab worth $22.8M as of Q2 2026.
  • Marshall Wace bought 814,659 Genmab shares in Q2 2026, an estimated $21.7M.
  • Genmab made up 0.02% of Marshall Wace's portfolio in Q2 2026, its #666 holding.
  • Marshall Wace first reported a position in Genmab in Q1 2020 and has held it in 18 quarters since.
  • Marshall Wace's Genmab position peaked at $42.7M in Q1 2025.
  • 292 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.